Berlin - Delayed Quote EUR

Bone Therapeutics SA (BT1.BE)

Compare
0.0093 +0.0005 (+5.68%)
At close: October 25 at 5:11 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for BT1.BE

Recent News: BT1.BE

View More
BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.

BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.
BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors

BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors
BioSenic reports half year 2024 results

BioSenic reports half year 2024 results
Véronique Pomi-Schneiter stands down as BioSenic's Deputy CEO

Véronique Pomi-Schneiter stands down as BioSenic's Deputy CEO
Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosis

Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosis
Medsenic/BioSenic patent granted in Japan for more protection of its therapeutic platform

Medsenic/BioSenic patent granted in Japan for more protection of its therapeutic platform
BioSenic S.A. : Transparency notification received from Mr Fran?ois Rieger

BioSenic S.A. : Transparency notification received from Mr Fran?ois Rieger
BioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHD

BioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHD
BioSenic S.A. : Transparency notification received from Véronique Pomi

BioSenic S.A. : Transparency notification received from Véronique Pomi
Medsenic, subsidiary of BioSenic SA, extends key patent to the United States

Medsenic, subsidiary of BioSenic SA, extends key patent to the United States
Medsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd.

Medsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd.
View More

Related Tickers